Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.

Hibma JE, Kantarjian HM, DeAngelo DJ, Boni JP.

Br J Clin Pharmacol. 2019 Mar;85(3):590-600. doi: 10.1111/bcp.13832. Epub 2019 Jan 21.

PMID:
30536405
2.

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.

Danesi R, Boni JP, Ravaud A.

Cancer Treat Rev. 2013 Nov;39(7):784-92. doi: 10.1016/j.ctrv.2012.12.012. Epub 2013 Jan 30. Review.

PMID:
23375248
3.

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.

Boni JP, Leister C, Hug B, Burns J, Sonnichsen D.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1433-42. doi: 10.1007/s00280-012-1845-7. Epub 2012 Feb 26.

PMID:
22367193
4.

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.

Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan R, Boni JP, Berkenblit A, Spunt SL.

Eur J Cancer. 2012 Jan;48(2):253-62. doi: 10.1016/j.ejca.2011.09.021. Epub 2011 Oct 25.

5.

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ.

J Clin Oncol. 2011 Jul 20;29(21):2933-40. doi: 10.1200/JCO.2010.33.4649. Epub 2011 Jun 20.

6.

Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.

Boni JP, Hug B, Leister C, Sonnichsen D.

Semin Oncol. 2009 Dec;36 Suppl 3:S18-25. doi: 10.1053/j.seminoncol.2009.10.009. Review.

PMID:
19963096
7.

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

Buckner JC, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, Berkenblit A, Rowinsky EK.

Invest New Drugs. 2010 Jun;28(3):334-42. doi: 10.1007/s10637-009-9257-1. Epub 2009 May 5.

PMID:
19415181
8.

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

Boni JP, Leister C, Burns J, Hug B.

Br J Cancer. 2008 Jun 3;98(11):1797-802. doi: 10.1038/sj.bjc.6604376. Epub 2008 May 6.

9.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
10.

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK.

Clin Cancer Res. 2006 Oct 1;12(19):5755-63.

11.

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK.

J Clin Oncol. 2006 May 20;24(15):2252-60.

PMID:
16710023
12.

Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.

Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME.

Clin Pharmacol Ther. 2005 Jan;77(1):76-89.

PMID:
15637533
13.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.

J Clin Oncol. 2004 Mar 1;22(5):909-18.

PMID:
14990647
14.

Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis.

Boni JP, Korth-Bradley JM, Martin P, Simcoe DK, Richards LS, Rennebohm R, Walson PD.

Clin Ther. 1999 Oct;21(10):1715-24.

PMID:
10566567
15.

The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects.

Boni JP, Cevallos WH, DeCleene S, Korth-Bradley JM.

Pharmacotherapy. 1997 Jul-Aug;17(4):783-90.

PMID:
9250558
16.

Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers.

Boni JP, DeCleene SA, Cevallos WH, Hicks DR, Korth-Bradley JM.

Ann Pharmacother. 1997 Apr;31(4):400-5.

PMID:
9100998
17.

Bromfenac disposition in patients with impaired kidney function.

Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM.

Clin Pharmacol Ther. 1997 Mar;61(3):312-8.

PMID:
9084456
19.

Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response.

Boni JP, Barr WH, Martin BR.

J Pharmacol Exp Ther. 1991 Apr;257(1):307-15.

PMID:
2019993
20.

Pyrolysis and volatilization of cocaine.

Martin BR, Lue LP, Boni JP.

J Anal Toxicol. 1989 May-Jun;13(3):158-62.

PMID:
2755088

Supplemental Content

Support Center